



PRESS RELEASE Switzerland

For further information, please contact:

Ulf Jönsson, President & CEO
Biacore International SA
Tel: +41 32 720 9083

Lars-Olov Forslund, EVP & CFO
Biacore International SA
Tel: +41 32 720 9084

Francis Sermet, Managing Director
Economic Promotion
Tel: +41 32 889 6823

Biacore Opens New Corporate Headquarters and Industrial Center in Switzerland

Neuchâtel, Switzerland, June 3, 2002. The Swedish based Biacore International AB today inaugurated its new corporate headquarters in Neuchâtel, Switzerland. The Company's Group Management, including CEO Ulf Jönsson, CFO Lars-Olov Forslund, and Executive Vice President of Human Resources Anders Svenberg, will be located alongside Biacore's Pharmaceutical & Biotechnology Industry Business Unit, which is currently based in Neuchâtel. As a result of this move, the Company's Swiss operation will play an important role in the strategic development of the Group.

The company is currently investing in building up its global logistics center in Neuchâtel together with part of its current manufacturing.

Commenting on the announcement, Ulf Jönsson said: “The Neuchâtel area provides access to a wealth of talented people that is important to the continuing development of Biacore’s global business. Take this, combined with the improved access to Europe’s major pharmaceutical companies and potential partners for Biacore, and the move to Switzerland makes a lot of sense strategically for the company. We are also very pleased with the support we have got in this establishment from the Government and the Economic Promotion of the Canton of Neuchâtel.”

– Ends –

Cautionary Statement

This press release contains certain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, which, by their nature, involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

About Biacore

Biacore is a global market leader in Surface Plasmon Resonance (SPR) based technology with its own sales operations in the U.S., across Europe, in Japan, Australia and New Zealand. The technology is protected by a strong patent portfolio. Target groups consist primarily of medical and life science research laboratories and pharmaceutical and biotechnology companies all over the world. Biacore focuses on drug discovery and development as the prime areas for future growth. The Company currently has seven systems on the market with its Biacore® S51 for applications downstream of high-throughput screening (HTS), including rapid characterization of HTS hits and comprehensive preclinical evaluation of lead compounds. Biacore® 3000 offers specific applications in drug discovery upstream of HTS. Biacore® C is specifically designed for compliant concentration analysis of biopharmaceuticals in GLP/GMP applications. A new SPR array system is currently under development.

Based in Uppsala, Sweden, the Company is listed on Stockholmsbörsen and Nasdaq in the U.S. In 2001 the Company had sales of SEK 544 million and an operating income of SEK 64 million.

Further information on Biacore can be found on the web: www.biacore.com

Address and phone:

*Biacore International SA
Puits-Godet 12, CH-2000 Neuchâtel, SWITZERLAND
Phone: +41 (0)32-720 90 00 Fax: +41 (0)32-720 90 01
e-mail: info@biacore.com*